Two new Finnish studies show that short bouts of light or moderate exercise can increase the number of immune cells in the bloodstream of cancer patients.
In a new study, American Cancer Society researchers discovered deaths with cancer as the underlying or primary cause decreased in the United States during the first year of the pandemic in 2020 compared to 2019, continuing the decreasing trend from prior years. In contrast, mortality rates with cancer as a contributing cause were higher in 2020 compared to 2019, reversing the decreasing trend from prior years. The study was published today in the Journal Oncology Practice.
Up to 50 percent of cancer-signaling proteins once believed to be immune to drug treatments due to a lack of targetable protein regions may actually be treatable, according to a new study from the Perelman School of Medicine at the University of Pennsylvania. The findings, published this month in Nature Communications, suggest there may be new opportunities to treat cancer with new or existing drugs.
A Michigan State University researcher is part of an international team that found an existing drug may help decrease side effects of cisplatin, a widely used cancer treatment that was discovered at MSU in 1965.
A new study led by researchers at the American Cancer Society and Clemson University shows residential racial and economic segregation was associated with cancer mortality at the county level in the United States.
Researchers at UC San Diego School of Medicine and Moores Cancer Center at UC San Diego Health describe the first preclinical model of appendiceal cancer that contains all elements of the tumor, allowing previously stymied investigations to proceed.
A new large study led by researchers at the American Cancer Society shows older age and smoking are the two most important risk factors associated with a relative and absolute five-year risk of developing any cancer. The findings also demonstrate that in addition to age and smoking history, clinicians should consider excess body fatness, family history of any cancer, and several other factors that may help patients determine if they may benefit from enhanced cancer screening or prevention interventions. The data was published today in the journal Cancer.
Featured studies include clinical advances with a new combination therapy targeting angiogenesis in platinum-resistant ovarian cancer and a promising immunotherapy combination for kidney cancer, plus laboratory studies that focus on targeting ferroptosis in specific lung cancers, developing chimeric antigen receptor (CAR) T cell therapies for blastic plasmacytoid dendritic cell neoplasms, and characterizing racial and ethnic disparities in breast cancer early detection.
More scientific evidence about the importance of nutrition and physical activity for cancer survivors has emerged in the past 10 years, prompting the American Cancer Society (ACS) to update its guidance for physicians and patients.
From 2004 to 2017, there was an increase in cancer of the appendix in acute appendicitis patients, especially among patients younger than 50 years old.
In a first-of-its-kind study, research from the University of Vermont Cancer Center has linked phthalates, commonly called the “everywhere chemical,” to higher incidence of specific childhood cancers.
Hyaluronic acid, or HA, is a known presence in pancreatic tumors, but a new study from researchers at the University of Michigan Health Rogel Cancer Center shows that hyaluronic acid also acts as food to the cancer cells. These findings, recently published in eLife, provide insight into how pancreatic cancer cells grow and indicate new possibilities to treat them.
Patients with melanoma who reported eating more fiber-rich foods when they began immunotherapy treatment survived longer without cancer growth than patients with insufficient dietary fiber intake, according to new research from The University of Texas MD Anderson Cancer Center published today in Science.
The final results from a national phase 2 study including researchers from Yale Cancer Center show the drug tipifarnib increased survival rates for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The findings are being presented today at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia.
Young patients with chronic lymphocytic leukemia (CLL) can enjoy long remissions on the drug ibrutinib, but must stay on it indefinitely to keep the cancer in remission. A new study by Dana-Farber Cancer Institute researchers suggests that a 2.5-year regimen involving ibrutinib and chemoimmunotherapy can provide deep, and lasting remissions of the disease.
Mount Sinai researchers have solved a major mystery in cancer research: How cancer cells remain dormant for years after they leave a tumor and travel to other parts of the body, before awakening to create metastatic cancer.
FDA approved an imaging drug known as Cytalux (pafolacianine), which is attracted to ovarian cancer tissue and illuminates it when exposed to fluorescent light, allowing surgeons to more easily find and more precisely remove the cancer.
It’s well known that smoking causes lung cancer. But a new study suggests you can lower―or even erase―the risk of dying from lung cancer associated with continuous smoking if you quit when you’re young.
Stress can have a significant negative effect on health, but our understanding of how stress impacts the development and progression of cancer is just beginning. A team from Roswell Park Comprehensive Cancer Center has identified an important mechanism by which chronic stress weakens immunity and promotes tumor growth. Their findings, just published in Cell Reports, point to the beta-adrenergic receptor (β-AR) as a driver of immune suppression and cancer growth in response to stress, opening the possibility of targeting this receptor in cancer therapy and prevention.